Moderna-Merck Skin Cancer Treatment Shows Long-Term Benefits
A personalized cancer treatment developed by Moderna Inc. and Merck & Co. helped prevent the recurrence of high-risk skin cancer after five years, new data confirming its prolonged benefit show.
By Gerry Smith · Bloomberg
A personalized cancer treatment developed by Moderna Inc. and Merck & Co. helped prevent the recurrence of high-risk skin cancer after five years, new data confirming its prolonged benefit show.